Inovio Pharmaceuticals
About: Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Employees: 134
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,018% more call options, than puts
Call options by funds: $436K | Put options by funds: $39K
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
3% more funds holding
Funds holding: 104 [Q4 2024] → 107 (+3) [Q1 2025]
0.07% more ownership
Funds ownership: 37.02% [Q4 2024] → 37.09% (+0.07%) [Q1 2025]
9% less capital invested
Capital invested by funds: $24.5M [Q4 2024] → $22.2M (-$2.3M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
50%
upside
Avg. target
$7
250%
upside
High target
$13
550%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
RBC Capital Gregory Renza | 150%upside $5 | Sector Perform Reiterated | 14 May 2025 |
Oppenheimer Jay Olson | 550%upside $13 | Outperform Maintained | 14 May 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 50%upside $3 | Neutral Reiterated | 19 Mar 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call.
Negative
Zacks Investment Research
1 month ago
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago.
Neutral
PRNewsWire
1 month ago
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25 Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025 INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production Preprint manuscript available on ResearchSquare.com PLYMOUTH MEETING, Pa. , May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments.
Neutral
Seeking Alpha
1 month ago
Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference.
Neutral
PRNewsWire
1 month ago
INOVIO to Present at Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa. , April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York.
Neutral
PRNewsWire
1 month ago
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
PLYMOUTH MEETING, Pa. , April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025.
Positive
Zacks Investment Research
1 month ago
Bet on These 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
Positive
Zacks Investment Research
2 months ago
Inovio (INO) Upgraded to Buy: Here's What You Should Know
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
PRNewsWire
2 months ago
INOVIO to Present at Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa. , April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference.
Positive
Zacks Investment Research
2 months ago
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Charts implemented using Lightweight Charts™